Stopping diarrhea

The term 'Stopping diarrhea' describes a clinical therapeutic outcome or indication rather than a single molecular target or receptor. It encompasses the physiological process of reducing bowel movement frequency and increasing stool consistency. This effect is mediated through various distinct molecular pathways in the gastrointestinal tract, most notably the mu-opioid receptors, which decrease muscular activity in the gut wall to slow transit time, and secretory pathways like the cystic fibrosis transmembrane conductance regulator (CFTR), which are targeted to reduce the secretion of water into the intestinal lumen (StatPearls, 2023). Clinically, 'stopping diarrhea' is a primary goal in treating conditions such as acute viral gastroenteritis, traveler's diarrhea, and chronic conditions like irritable bowel syndrome with diarrhea (IBS-D). While highly effective for symptom management, pharmacological intervention must be used cautiously in cases of bacterial or parasitic infections where inhibiting gut motility may delay the clearance of pathogens or toxins from the body (NIH, 2022; PubMed, 2021).

Other names

Antidiarrheal therapyDiarrheal reliefReduction of fecal urgencyManagement of intestinal hypermotility

Stopping diarrhea is achieved through multiple mechanisms depending on the drug used: mu-opioid receptor agonism slows intestinal peristalsis; enkephalinase inhibition reduces intestinal hypersecretion; chloride channel (CFTR) inhibition prevents fluid loss; and somatostatin analogues inhibit the release of serotonin and other gastrointestinal peptides (StatPearls, 2023; NIH, 2022).